| [1] |
Couser WG. Primary membranous nephropathy [J]. Clin J Am Soc Nephrol, 2017, 12(6): 983-997.
|
| [2] |
Tomas NM, Huber TB, Hoxha E. Perspectives in membranous nephropathy [J]. Cell Tissue Res, 2021, 385(2): 405-422.
|
| [3] |
Ahmad SB, Appel GB. Antigens, antibodies, and membranous nephropathy: a decade of progress [J]. Kidney Int, 2020, 97(1): 29-31.
|
| [4] |
Matsuhashi S, Noji S, Koyama E, et al. New gene, nel, encoding a M(r) 93 K protein with EGF-like repeats is strongly expressed in neural tissues of early stage chick embryos [J]. Dev Dyn, 1995, 203(2): 212-222.
|
| [5] |
Watanabe TK, Katagiri T, Suzuki M, et al. Cloning and characterization of two novel human cDNAs (NELL1 and NELL2) encoding proteins with six EGF-like repeats[J]. Genomics, 1996, 38(3): 273-276.
|
| [6] |
Li C, Zhang X, Zheng Z, et al. Nell-1 is a key functional modulator in osteochondrogenesis and beyond [J]. J Dent Res, 2019, 98(13): 1458-1468.
|
| [7] |
Sethi S. New 'antigens’ in membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(2): 268-278.
|
| [8] |
Nakamura R, Oyama T, Tajiri R, et al. Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma [J]. Cancer Sci, 2015, 106(5): 656-664.
|
| [9] |
Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies [J]. Lancet, 2004, 364(9441): 1252-1259.
|
| [10] |
Beck LH, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
|
| [11] |
Tomas NM, Beck LH, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy [J]. N Engl J Med, 2014, 371(24): 2277-2287.
|
| [12] |
Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy [J]. Kidney Int, 2019, 95(3): 666-679.
|
| [13] |
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases [J]. Kidney Int, 2021, 100(4S): S1-S276.
|
| [14] |
Berchtold L, Zanetta G, Dahan K, et al. Efficacy and safety of rituximab in hepatitis B virus-associated PLA2R-positive membranous nephropathy [J]. Kidney Int Rep, 2018, 3(2): 486-491.
|
| [15] |
Thet Z, Lam AK, Ranganathan D, et al. Critical evaluation of cancer risks in glomerular disease [J]. Transl Oncol, 2022, 19: 101376.
|
| [16] |
Ronco P, Debiec H. Membranous nephropathy: current understanding of various causes in light of new target antigens [J]. Curr Opin Nephrol Hypertens, 2021, 30(3): 287-293.
|
| [17] |
Ronco P, Plaisier E, Debiec H. Advances in membranous nephropathy [J]. J Clin Med, 2021, 10(4): 607.
|
| [18] |
Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/exostosin 2-associated membranous nephropathy [J]. J Am Soc Nephrol, 2019, 30(6): 1123-1136.
|
| [19] |
Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy [J]. Kidney Int, 2020, 97(1): 163-174.
|
| [20] |
Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients [J]. Kidney Int, 2020, 98(5): 1253-1264.
|
| [21] |
Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis [J]. Kidney Int, 2021, 100(1): 171-181.
|
| [22] |
Wang G, Sun L, Dong H, et al. Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients [J]. Clin J Am Soc Nephrol, 2021, 16(5): 727-735.
|
| [23] |
Kudose S, Santoriello D, Debiec H, et al. The clinicopathologic spectrum of segmental membranous glomerulopathy [J]. Kidney Int, 2021, 99(1): 247-255.
|
| [24] |
Zhang D, Zhang C, Bian F, et al. Clinicopathological features in membranous nephropathy with cancer: a retrospective single-center study and literature review [J]. Int J Biol Markers, 2019, 34(4): 406-413.
|
| [25] |
Beck LH. Membranous nephropathy and malignancy [J]. Semin Nephrol, 2010, 30(6): 635-644.
|
| [26] |
Birkeland SA, Storm HH. Glomerulonephritis and malignancy: a population-based analysis [J]. Kidney Int, 2003, 63(2): 716-721.
|
| [27] |
Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy [J]. Kidney Int, 2021, 99(4): 967-976.
|
| [28] |
Plaisier E, Ronco P. Screening for cancer in patients with glomerular diseases [J]. Clin J Am Soc Nephrol, 2020, 15(6): 886-888.
|
| [29] |
Kun E, Tsang YTM, Ng CW, et al. MEK inhibitor resistance mechanisms and recent developments in combination trials [J]. Cancer Treat Rev, 2021, 92: 102137.
|
| [30] |
Caspi M, Wittenstein A, Kazelnik M，et al. Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders [J]. Adv Drug Deliv Rev, 2021, 169: 118-136.
|
| [31] |
Sethi S, Madden B, Debiec H, et al. Protocadherin 7-associated membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(5): 1249-1261.
|
| [32] |
Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(7): 1666-1681.
|
| [33] |
Stefan G, Stancu S, Zugravu A, et al. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy [J]. Renal failure, 2022, 44(1): 258-268.
|